Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.82 |
| ▸ | AURKA | O14965 | 10/20 | 0.66 |
| ▸ | EGFR | P00533 | 7/20 | 0.66 |
| ▸ | KDR | P35968 | 5/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.66 |
| ▸ | SRC | P12931 | 3/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | RET | P07949 | 1/20 | 0.66 |
| ▸ | MET | P08581 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.66 |
| ▸ | LTK | P29376 | 1/20 | 0.66 |
| ▸ | TTK | P33981 | 1/20 | 0.66 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.66 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.66 |
| ▸ | BTK | Q06187 | 1/20 | 0.66 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15963665 | 0.91 | HDAC1 (0.69) | HDAC1AURKAEGFRKDRAURKB | |
| SCHEMBL15519470 | 0.90 | HDAC1 (1.00) | HDAC1AURKAEGFRKDRAURKB | |
| SCHEMBL15520326 | 0.87 | EGFR (0.66) | HDAC1AURKAEGFRKDRAURKB | |
| SCHEMBL15518978 | 0.84 | HDAC1 (0.69) | HDAC1EGFRKDRLCK | |
| SCHEMBL15519763 | 0.83 | HDAC1 (0.58) | HDAC1AURKAEGFRKDRAURKB | |
| SCHEMBL15579855 | 0.81 | HDAC1 (1.00) | HDAC1AURKAEGFRKDRAURKB | |
| SCHEMBL210211 | 0.80 | HDAC1 (0.70) | HDAC1 | |
| SCHEMBL6949133 | 0.80 | EGFR (0.82) | HDAC1AURKAEGFRKDRAURKB | |
| SCHEMBL29377224 | 0.80 | EGFR (1.00) | HDAC1AURKAEGFRKDRAURKB | |
| SCHEMBL597105 | 0.80 | EGFR (1.00) | HDAC1AURKAEGFRKDRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034886-B2 | 4-aminoquinazoline derivatives and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-05-19 | — | — | US | claimed |
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-08-21 | — | — | US | claimed |
| EP-2708532-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF | Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) | 2014-03-19 | — | — | EP | claimed |
| US-9034886-B2 | 4-aminoquinazoline derivatives and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-05-19 | — | — | US | disclosed |
| US-9034886-B2 | 4-aminoquinazoline derivatives and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-05-19 | — | — | US | disclosed |
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-08-21 | — | — | US | disclosed |
| EP-2708532-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF | Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) | 2014-03-19 | — | — | EP | disclosed |
| EP-2708532-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND USES THEREOF | Jiangsu Hengyi Pharmaceutical Co.,Ltd (CN) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235633-A1 | 4-Aminoquinazoline Derivatives and Uses Thereof | HDAC5, HDAC4, HDAC1 | HDAC1 3/4885AURKA 239/4885EGFR 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.